The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

This designation highlights the potential of amlenetug as a treatment option for people living with Multiple System Atrophy. We are hopeful of the potential for amlenetug to slow the clinical ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

Afflicting an estimated four in 100,000 people, Multiple System Atrophy (MSA) causes gradual damage to nerve cells in the brain, affecting movement, balance and basic functions like breathing ...

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.